ABOS Key Statistics, Chart & Performance
The current stock price of ABOS is 2.1 USD. In the past month the price increased by 32.91%. In the past year, price increased by 13.51%.
ABOS Latest News, Press Relases and Analysis
ABOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.67 | 395.31B | ||
| AMGN | AMGEN INC | 14.94 | 175.94B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 147.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.21 | 115.43B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.58 | 78.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767 | 51.68B | ||
| INSM | INSMED INC | N/A | 42.80B | ||
| NTRA | NATERA INC | N/A | 31.38B | ||
| BIIB | BIOGEN INC | 10.24 | 25.16B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.95 | 21.53B | ||
| INCY | INCYTE CORP | 15.11 | 19.05B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ABOS
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
Company Info
ACUMEN PHARMACEUTICALS INC
1210-1220 Washington Street, Suite 210
Newton MASSACHUSETTS US
CEO: Daniel O'Connell
Employees: 61
Phone: 16173444190
ACUMEN PHARMACEUTICALS INC / ABOS FAQ
What does ABOS do?
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
What is the current price of ABOS stock?
The current stock price of ABOS is 2.1 USD. The price increased by 1.94% in the last trading session.
Does ABOS stock pay dividends?
ABOS does not pay a dividend.
How is the ChartMill rating for ACUMEN PHARMACEUTICALS INC?
ABOS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for ACUMEN PHARMACEUTICALS INC?
ACUMEN PHARMACEUTICALS INC (ABOS) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of ACUMEN PHARMACEUTICALS INC (ABOS)?
ACUMEN PHARMACEUTICALS INC (ABOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
What is ACUMEN PHARMACEUTICALS INC worth?
ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 127.20M USD. This makes ABOS a Micro Cap stock.
ABOS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABOS. When comparing the yearly performance of all stocks, ABOS is one of the better performing stocks in the market, outperforming 91.45% of all stocks.
ABOS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABOS. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative.
ABOS Financial Highlights
Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -62.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.76% | ||
| ROE | -143.12% | ||
| Debt/Equity | 0.29 |
ABOS Forecast & Estimates
11 analysts have analysed ABOS and the average price target is 6.63 USD. This implies a price increase of 215.71% is expected in the next year compared to the current price of 2.1.